Small Molecule Modulation of the Integrated Stress Response Governs the Keratoconic Phenotype In Vitro

Uri Simcha Soiberman,1 Ahmed Elsayed Mahmoud Shehata,2 Michelle Xiaoyi Lu,3 Tempest Young,3 Yassine J. Daoud,1 Shukti Chakravarti,4 Albert S. Jun,1 and James William Foster1

1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt
3Johns Hopkins University, Baltimore, Maryland, United States
4Department of Ophthalmology, NYU Langone Health, New York, New York, United States

Correspondence: James William Foster, Wilmer Eye Institute, Smith M037, 400 North Broadway, Baltimore, MD 21231, USA; JFoste41@jhmi.edu.
Submitted: March 26, 2019
Accepted: July 7, 2019

PURPOSE. The degenerative corneal disease keratoconus is a leading indicator for corneal transplant with an unknown etiology. We recently identified the activation of the integrated stress response (ISR) in ex vivo human corneas and in vitro cell culture. Utilizing small molecules to modulate the ISR we sought to investigate the effects of stimulating the ISR in healthy cells to recapitulate aspects of the in vitro keratoconic phenotype and whether relieving the ISR signaling would recover the disease phenotype.

METHODS. Corneal fibroblasts were extracted from patients undergoing corneal transplant or unaffected cadaverous donor limbal rings. Cells were exposed to the DNA damage-inducible protein (GADD34) inhibitor SAL003 to stimulate the ISR, or Trans-ISRIB to relieve ISR signaling pathway. Collagen production was assessed through hydroxyproline production, Sirius Red incorporation, or quantitative (q)PCR. Western blotting, hydroxyproline, and qPCR were used to assess components of the ISR pathway and collagen production.

RESULTS. ISR stimulation through SAL003 resulted in significant decrease of hydroxyproline and COL1A1 transcription and eventual apoptosis in normal fibroblasts. Patient (KC) fibroblast production of hydroxyproline was increased in response to ISR, while matrix metalloproteinase (MMP)9 production was lowered. The prospective biomarker of keratoconus prolactin-inducible factor was also upregulated in KC fibroblast cultures in response to ISRIB. Inflammatory markers TNFα and IL-1β were unaffected.

CONCLUSIONS. Activation of the ISR is sufficient to recapitulate many key aspects of the KC phenotype in unaffected cells in vitro. Inhibition of the ISR also relieves many of the hallmarks of KC in affected cells. Therefore, targeting of the ISR through small molecules is a potential therapeutic path for small molecule treatment of keratoconus.

Keywords: keratoconus, cell stress, collagen, ISR, ATF4

Keratoconus is a degenerative corneal disease with an incidence rate of 50 to 265 per 100,000 and onset in early adolescence.1–4 The only available treatment for progressive keratoconus, corneal collagen crosslinking, is an effective method of slowing down or halting progression in keratoconus.5 However, this modality does not address the underlying biological processes that lead to disease pathogenesis, nor do other treatments aimed at visual rehabilitation, such as contact lens wear, intracorneal ring segments, or corneal transplants.6 Currently, there is no small molecule intervention strategy for the treatment of keratoconus either to halt or reverse the progression of this disease. We recently identified the activation of the integrated stress response (ISR) in ex vivo keratoconic corneas and in vitro human corneal fibroblasts, although the mechanism and results of this activation were not elucidated.7

The goal of this research was to investigate the effects of ISR modulation on normal (DN) and patient (KC) corneal fibroblasts in vitro, the hypothesis being that ISR activation in DN fibroblasts confers a keratoconic phenotype. Conversely, relief of the ISR signaling in KC fibroblasts would recover a more DN phenotype.

Previous in vitro studies have repeatedly demonstrated that reduced extracellular matrix (ECM) production is a hallmark of keratoconus fibroblasts.7–9 There are also multiple studies that have demonstrated increased production of catabolic enzymes such as matrix metalloproteinases (MMPs) in KC both in vitro and in vivo.8 The effects on the expression of ECM proteins, MMPs, and proteins associated with their activity in the context of the ISR have not been thoroughly investigated and have implications for understanding of the pathogenesis of diseases beyond keratoconus.

The ISR is a powerful and conserved signaling pathway that coordinates cellular responses to multiple acute and chronic intracellular and extracellular cellular stresses.9,10 A central node of activation is the phosphorylation of serine S1 (S51) of eukaryotic translation initiation factor 2 subunit 1 (eIF2α); this phosphorylation leads to inhibition of eIF2B and repression of cap-dependent translation.11 Accumulation of p-eIF2α also leads to the transcription of the active uORF2 of ATF4.12 Once translated, ATF4 translocates to the nucleus and acts as a transcription factor stimulating the production of cap-independent proteins that alter cell survival networks such as...
metabolite usage,9 cytokine production,13 autophagy,14 protein folding,15 and ultimately apoptosis.16 Of note, hallmarks of keratoconus ex vivo and in vitro include altered autophagy profile, altered metabolites,17 altered cytokines,18 increased expression of protein chaperones such as CRP55, and loss of anterior stromal keratocytes.19

Critically, we have observed high levels of p-eIF2α and nuclear ATF4 in ex vivo human KC corneas, although the implications of this activation were not investigated.20 SAL003 is a cell-permeable inhibitor of the eIF2α phosphatase GADD3421; this inhibition causes an increase in phosphorylated eIF2α concentration and a nonspecific activation of the ISR. Depending on the context and duration, this activation has been shown to result in cellular adaptation and survival, or at high concentrations induction of apoptosis.22

In contrast, the small molecule integrated stress response inhibitor and its isomer trans-ISRIB (ISRIB) have been identified as a powerful (IC50, 5 nM) agonist of eIF2β by promoting the assembly of the eIF2B decamer and increasing its abundance in treated cells. This accumulation is posited to confer resistance to lower levels of ISR activation observed in vivo and in vitro by restoring cellular translation capacity and relieving the cells of the effects of an active ISR.

In this study we sought to correlate our findings of the active ISR in keratoconus in an in vitro setting by manipulating cell cultures with SAL or ISRIB with a focus on the effects of these molecules on collagen and MMP production in primary human corneal fibroblasts.

We first investigated the effects of an active ISR on the behavior of normal corneal keratocytes (DN) to ascertain whether activation recapitulates the observed in vitro collagen production phenotype of keratoconus. Second, we examined whether ISRIB could rescue the stimulated (DN) or diseased (KC) phenotype. We observed that by stimulating the ISR in vitro we significantly decrease the production of ECM, raise the production of catabolic enzymes (MMP2), and increase the intracellular concentration of transport proteins (CALR). We observed that ISR inhibition through ISRIB was capable of partially rescuing the excessive production of MMP2 and enhanced the production of ECM proteins in multiple KC fibroblast lines. Finally, we detected that only KC fibroblasts are responsive to ISRIB especially in their active state, and that the production of COL1A1 and prolactin-induced protein (PIP), a putative KC marker, is responsive to the ISR status of the cells.26 The observation that ISR modulation is sufficient to cause and relieve the symptoms of the in vitro KC ECM phenotype in multiple independent patient samples raises the possibility of ISR modulation being a potential therapeutic intervention in the treatment of KC.

**METHODS**

**Ethics Statement**

All human tissue was obtained under established guidelines related to informed consent for research use of human donor and patient corneas and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from keratoconus patients using a protocol approved by the Johns Hopkins Medicine Institutional Review Board and titled “Phenotypic and Genotypic Analysis of Keratoconus” (NA_00006544). Control, healthy keratocytes were obtained from anterior stromal caps derived from healthy cadaveric corneas used for endothelial keratoplasty that are screened for keratoconus by means of anterior segment optical coherence tomography.

**Cell Culture**

Human stromal cells were extracted as described previously from cadaverous corneal donors (Lions Eye Bank, Baltimore, MD, USA, and Lions Eye Institute for Transplant and Research, Tampa, FL, USA), or obtained with consent from surgical samples after corneal transplantation in confirmed keratoconus patients (Wilmer Eye Institute, Baltimore, MD, USA). A total of seven individual patient cell lines were used in this study. No patients had a recorded family history of keratoconus, and patients ranged in age from 18 to 55 at the time of transplantation. Male (five) and female (two) samples were used; the reported ethnicities were Caucasian, Middle Eastern, and African American.

Briefly, epithelial and endothelial cells were removed by scraping; stromal pieces were then cut into small pieces and incubated in 1 mg/mL collagenase in fibroblast growth medium (FGM), Dulbecco’s modiﬁed Eagle’s medium (DMEM):F12 media containing 5% fetal bovine serum, 1 mM phospho-ascorbic acid, 1% antibiotic/antimycotic solution (FGM) for 3 hours at 37°C. Cells were then centrifuged and released from ECM debris by treating with 0.1% trypsin/EDTA solution for 5 minutes. Trypsin was then neutralized with FGM, and the cell solution was passed through a 70-μm cell strainer. Cells were pelleted and then resuspended in FGM and plated on tissue culture plates and allowed to divide; media were replaced every 2 or 3 days until reaching 80% confluence, after which the cells were frozen for later use or directly used for experiments. All primary cells used in the investigations detailed below were under four passages. SAL003 (PubChem ID 5717757; pubchem.ncbi.nlm.nih.gov) and Trans-ISRIB (PubChem ID 1011240) were resuspended in dimethyl sulfoxide. For serum-free culture, cells were plated and allowed to adhere overnight, media was then exchanged for a low-glucose serum-free (LG5F) media consisting of low-glucose DMEM, 1 mM phospho-ascorbic acid, 1% antibiotic/antimycotic solution, 1% insulin, transferrin, selenium (cat. no. 41400045; Thermo Fisher, Waltham, MA, USA).

**Determination of Cell Number**

Cell number was derived utilizing the Alamar Blue/resazurin (R7017; Sigma-Aldrich, St. Louis, MO, USA) reduction assay. A working concentration of 5.5 μM resazurin in media was used at each media change and then incubated at 37°C for 50 minutes. The fluorescence was then measured on a fluorimeter with a 540-nm excitation and 590-nm emission; each well was read in duplicate on a fluorescent plate reader (Safire 2; Tecan, Männedorf, Switzerland) and cell number derived from standard curves of known cell number.

**MMP2 and 9 Expression**

Gelatin zymography was used to determine expression of MMP2 and MMP9 in response to small molecule inhibition as previously described.7,27 We utilized a modified zymography protocol that included the use of 2,2,2-trichloroethanol to enable the visualization of total protein prior to Coomassie blue staining to visualize gelatinases.28

**Total MMP Quantification**

The fluorometric MMP assay (ab112146; Abcam, Cambridge, UK) was utilized to determine total MMP activity in cell culture medium. Briefly, cell culture media were preactivated with 4-aminophenylmercuric acetate for 5 hours and then incubated with the fluorescence-resonance-energy-transfer–based MMP green substrate for 1 hour. The fluorescence intensity was then...
Collagen Quantification

Collagen production was assayed using a modified picro-sirius red/fast green incorporation assay. Cells were fixed for 15 minutes in 4% paraformaldehyde in PBS solution and then stained with 0.04% Fast Green (F7252; Sigma-Aldrich), dissolved in a picro-sirius red solution (STPSRPT; American Mastertech Scientific, McKinney, TX, USA) for 15 minutes. Cells were then washed three times with excess distilled water. The dyes were then eluted in 250 μL of 0.1% NaOH in methanol and absorbance at 540 and 605 nm. Total protein and collagen were determined using the following formulas:

\[
\text{Collagen} = \frac{OD540 - (OD605x0.291)}{0.0378}
\]

The 29.1% correction corresponds to the overlap between the Fast Green and Sirius Red absorbance spectrum and is required for accurate quantification. We also utilized the hydroxyproline assay to quantify collagen production by the cells. We utilized the Hydroxyproline kit (K555; BioVision, Milpitas, CA, USA) per the manufacturer's instructions. The hydroxyproline quantification was carried out using a standard curve as directed, with values normalized to final cell number.

Western Blotting

Cells were lysed in radioimmunoprecipitation assay buffer including protease and phosphatase inhibitors; protein was run on a 10% SDS Tris-glycine gel according to standard practices. After transfer to polyvinylidene difluoride membrane, membranes were blocked with 5% nonfat dry milk (Blotto) in PBS and then incubated in blocking buffer + 0.1% Tween 20 overnight with antibodies: ATF4 (ab184909; Abcam), Phospho S51 eIF2α (ab32157, 1:800; Abcam), eIF2α (9722, 1:100; Cell Signaling Technologies, Danvers, MA, USA), CRP55 (ab92516; 1:2000; Abcam). Detection was carried out using HRP labeled antibodies and ECL.

Immunohistochemistry

Fibroblast lines were plated on eight-well chamber slides and grown in FGM overnight; cells were then dosed with SAL (2.5 μM) or ISRIB (12.5 nM) or vehicle control for 3 days. Cells were then washed in PBS and fixed in 4% paraformaldehyde in PBS for 15 minutes. They were then permeabilized in 0.1% Triton X-100 in phosphate-buffered saline for 5 minutes. Slides were blocked in 5% PBS, 2% normal goat serum in PBS for 1 hour. ATF4 antibody (ab184909; Abcam) was diluted in blocking buffer 1:200 and incubated overnight at 4°C. After washing 3 × 15 minutes in PBS, secondary antibody (A-11034; Thermo Fisher) was diluated 1:500 in blocking buffer and incubated for 1 hour at room temperature. F-actin was visualized with Phalloidin, DyLight 650, (21838; Thermo Fisher) diluted 1:200 in blocking buffer was incubated for 15 minutes. Nuclei were visualized with 4',6-diamidino-2-phenylindole (DAPI). Images (×10) were obtained on a Zeiss Axio Imager A2 (Zeiss GMBH, Oberkothen, Germany) utilizing Axiosview software. High-magnification images were obtained on a Zeiss 510 Meta confocal microscope with a ×63 objective utilizing Zen software.

Transcriptional Analysis by qRT-PCR

RNA was extracted using the RNasey kit (Qiagen, Hilden, Germany) per manufacturer's instructions. Reverse transcription was carried out using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) with 500 ng RNA added per reaction. Quantitative (q)PCR was carried out utilizing SYBR Green standard conditions (3-step, 60°C annealing), using the CFX384 Touch Real-Time PCR machine (Bio-Rad). The primer sequences included in the Table were used. Expression was quantified using 2−ΔΔCt normalized to glyceraldehyde 3-phosphate dehydrogenase and the cell line control.

Statistics

Quantitative data are presented as mean ± SEM and were analyzed for statistical significance by unpaired, 2-tailed Student’s t-test or 1-way ANOVA using GraphPad Prism (San Diego, CA, USA). Significance is presented as *P < 0.05, **P < 0.01, ***P < 0.001.

RESULTS

Activation of the ISR in Healthy Cells Recapitulates the In Vitro Keratoconic Phenotype

We initially tested the effects of activation on cell survival, collagen production, and expression of proteins consistent with an active ISR after 3 days in culture in serum-containing media, which promotes keratocyte proliferation. We initially undertook a toxicity assay on three independent DN cell lines and observed profound toxicity at and above 5 μM (Fig. 1A). Analysis of the ISR pathway also demonstrated an increase in eIF2α phosphorylation, ATF4 expression, and CRP55 expression, demonstrating a dose-dependent increase in ISR activation due to SAL003 treatment (Fig. 1B). We therefore chose the concentration of 2.5 μM as the optimum concentration for further studies due to its lack of toxicity while still upregulating eIF2α phosphorylation (2.4-fold), increasing ATF4 expression (>50-fold), and increasing expression of the protein.
chaperone CRP55 (1.8-fold), which is known to be increased in situations of high ISR signaling. A longer-duration cell culture was used to assess changes in collagen production. Specifically, collagen turnover in keratocytes, especially in quiescent cells, was found to be very slow, and therefore short-duration cultures were unlikely to produce meaningful results. However, with a 10-day culture, we observed a decrease in collagen production in SAL003-treated cells cultured in serum-containing media (FBS). FBS generally promotes keratocyte expansion, whereas culture in serum-free (LGSF) more closely recapitulates the in vivo quiescent keratocyte phenotype. Therefore, collagen production was assessed also in keratocytes cultured in LGSF; we observed increased collagen production (when normalized to cell number) in LGSF cultures. When treated with SAL003 for the duration of culture we observed a decrease in hydroxyproline corresponding to a 39.8 ± 6.2% decrease in LGSF, and a 55.1 ± 6.8% decrease in FBS relative to vehicle control (Fig. 1C). ATF4 localization, a key indicator of ISR activation, was also observed in fibroblast cultures. In DN cells, there is mixed nuclear and cytoplasmic localization (Fig. 1D, i, iv) indicative of normal levels of ISR signaling. When treated with 2.5 μM SAL003, all ATF4 is localized to the nucleus of the cells (Fig. 1D, ii, v). For reference, the staining of control KC cells has been included, demonstrating nuclear localization (Fig. 1D, iii, vi). Individual channels and controls are included in Supplementary Figure S1.

Blocking of the ISR Can Relieve Aspects of the KC Phenotype In Vitro

The small molecule ISRIB is a potent inhibitor of the ISR, which we hypothesized would relieve some of the phenotypic changes observed in KC in vitro cultures. We first examined the effects of ISRIB on proliferation of KC fibroblasts over 4 days, as determined by an Alamar Blue assay (Fig. 2A). We detected no differences in doubling time in response to ISRIB dosing (50–6.25 nM), as expected. Additionally, we observed that SAL003 increased the doubling time from 26.8 ± 6.5 to 46.1 ± 13.4 hours. We assessed the effects of ISRIB on collagen...
production in KC keratocytes cultured in LGSF over 7 days, as determined by Sirius Red/Fast Green incorporation assay. At 12.5 nM ISRIB, we observed an increase in the percentage of collagenous proteins (Fig. 2B). As elevated MMP expression is a hallmark of KC, we examined the effects of ISRIB on the production of MMP2 as determined by gelatin zymography (Figs. 2C, 2D): When normalized to total protein we observed a dose-dependent decrease in MMP2 production (Fig. 2C). Taking all this together, we believe that 12.5 nM ISRIB is sufficient to relieve hallmark aspects of the KC ECM phenotype in vitro.

**Investigations of MMP Production**

We sought to understand the role of the ISR in regulation of MMP production; qPCR of key MMPs showed a significant increase in MMP9 transcription in KC cells relative to DN. However, no significant transcriptional differences were observed in response to either SAL or ISRIB treatments (Fig. 3A). In addition, the transcriptional levels of MMP3 and MMP13 were not affected by ISR modulation (Supplementary Fig. S3).

TIMP3, a major negative regulator of MMP activity, was shown to be significantly decreased in KC cells relative to DN cells (0.3 ± 0.2). Moreover, when treated with SAL the DN cells increased their expression (2.36 ± 0.6), whereas the KC cells barely increased their transcription to the resting levels of the DN cells (Fig. 3B). We next investigated whether the observed differences were specific to the ISR utilizing another ISR stimulating molecule, tunicamycin (TUN). Utilizing zymography we observed increased expression of MMP9 in response to both TUN (0.1 µg/mL) and SAL (2.5 µM) (Fig. 3C). Importantly, the increase in MMP9 expression could be diminished when ISRIB (12.5 µM) was included (Fig. 3C). While TUN caused an increase in MMP9 expression when normalized to cell number, it was profoundly toxic over the 3-day cultures (Fig. 3D; Supplementary Fig. S2). Finally, we investigated the total MMP production of the cells in response to SAL, ISRIB, and in combination. Utilizing a fluorescence-based reporter assay for all MMPs we observed an increase in total MMPs in SAL-treated KC cells only (1.76 ± 0.24 to 2.75 ± 0.61), and an increased trend in DN cells, though this did not reach significance ($P = 0.18$). In contrast to the zymography results, ISRIB addition was not capable of diminishing global MMP production. We did observe that KC cells produce more constitutively active MMP species than DN (Supplementary Fig. S5), suggesting that there is a difference in MMP species being produced by the KC fibroblasts (Fig. 3E).

**Differential Responses to ISR Modulation**

Having demonstrated the effects of both inducing and relieving the ISR in DN and KC fibroblast cultures, we sought to investigate whether DN and KC samples would behave differently when exposed to these small molecules. We first demonstrated the effects of the different dosing regimens on the activation of the ISR in DN and KC cells (Fig. 4A). We observed that the ratio of p-efF2α/total efF2α is markedly increased in KC cells as reported previously; as expected, the addition of SAL increases phosphorylation of efF2α in both DN and KC cells, though this effect is increased in KC cells. ISRIB dosing reduces the p-efF2α ratio to levels comparable to DN. The addition of both inhibitors increases the phosphorylation of efF2α in both DN and KC cells, though it does appear to suppress the expression to below that of SAL alone. Utilizing qPCR, we demonstrate that COL1A1 transcription is markedly decreased in response to SAL003 dosing in both DN and KC samples (0.068 ± 0.12, 0.16 ± 0.126, respectively). In DN samples, ISRIB appears to marginally increase COL1A1 transcription, though this did not reach significance ($1.32 ± 0.126$).
0.162-fold). However, in the KC samples we see significant upregulation of COL1A1 (from 0.88 ± 0.28- to 1.25 ± 0.24-fold), suggesting that ISRIB was capable of relieving the key hallmark of in vitro KC cultures, low collagen production (Fig. 4B). Utilizing hydroxyproline we observed a dose-dependent increase in response to ISRIB (DN 32%, KC 35%) and a corresponding decrease in response to SAL003 (DN 27%, KC 39%), in broad agreement with the qPCR results (Fig. 4C). We also sought to investigate whether an active ISR could stimulate expression of proinflammatory markers as there are well-reported changes in cytokines in the keratoconic eye. Analysis of IL-1β showed that both DN and KC fibroblasts have barely detectable levels of IL-1β transcription at baseline or when treated with ISRIB (Fig. 4D). However, when exposed to SAL there is an increased trend of IL-1β transcription in both DN and KC cells (P = 0.08, 0.12). TNFα expression was also assayed in the media and found to be barely detectable in most samples (Supplementary Fig. S5).

Finally, we investigated the expression of a candidate KC biomarker, the hormone prolactin-induced protein (PIP), which has been described as being reduced in KC patients, though the mechanism causing this reduction is unknown.27 Here we demonstrated that activation of the ISR in DN cells causes a decrease in transcription (0.19 ± 0.14). In contrast, blocking of the ISR through ISRIB in KC cells is sufficient to increase the transcription of PIP in vitro (0.57 ± 0.33- to 1.32 ± 0.38-fold) (Fig. 3E). Based on the data presented here we therefore believe that ISR activation underlies a majority of the previously described aspects of the KC in vivo and in vitro phenotypes.

**DISCUSSION**

We have previously described the activation of the ISR as a key hallmark of KC ex vivo and in vitro, although the causes and effects of this activation were unknown. In this study we sought to investigate the effects of ISR modulation on the behavior of healthy and diseased corneal fibroblasts to test the hypothesis that ISR activation could cause, and inhibition could recover, the in vitro ECM keratoconic phenotype. Utilizing the GADD34 inhibitor SAL003 in DN cells, we have determined the optimal dosing concentration to activate the ISR and trigger a KC-like phenotype, namely, decreased collagen production, increased MMP2, nuclear localization of ATF4, and increased CRP.7 We then demonstrated that attenuation of the ISR through the small molecule ISRIB is sufficient to increase the collagen production of KC fibroblasts while decreasing the production of MMP2 while having little effect on DN cells. We believe that this is due to the constitutive activation of the ISR in KC cells alone. We also observed complex regulation of MMPs and their inhibitory proteins in response to the ISR. The transcriptional
levels of several MMPs were unaffected by initiation of the ISR, whereas TIMP3, an inhibitor of MMP activity and a protein that has been previously reported as being underexpressed in KC corneas, was not stimulated in KC cells as it was in DN cells. This complex regulation of MMPs was also apparent when we investigated the global MMP expression levels, with SAL stimulating profound increases in total MMPs in KC cells only. Further investigations will focus on identifying those MMP species that are most responsive to the ISR stimulus.

Finally, we demonstrate that the effects of ISR modulation are specific to diseased cells, with ISRIB stimulating increased COL1A1 transcription and hydroxyproline production in KC cells only. We also investigated the expression of prospective inflammatory cytokines IL-1β and TNFα, which have been described as being dysregulated in keratoconus. We observed that both IL-1β and TNFα were not produced above the detection threshold by DN or KC fibroblasts under untreated conditions and, although there was a trend toward increased expression (by qPCR and ELISA), in both cases the levels of expression were barely above the detection threshold. As these cytokines and others have been reported in KC previously, this suggests that the increased levels observed are from other cell types. We also observed that the putative KC marker PIP is responsive to the ISR, and that stimulation in DN cells (recapitulating KC) is sufficient to suppress its transcription as is observed in the disease. Conversely in KC cells, relief of the ISR signaling with ISRIB is sufficient to cause an increase in its transcription.
The activation of the ISR has been associated with the pathogenesis of several diseases not related to the cornea, including Alzheimer's disease, diabetes mellitus, and several retinopathies. However, these investigations have been focused on the role of highly metabolically active cells rather than on fibroblasts. We believe that the corneal stroma is uniquely exposed to all the triggers that have been reported in the activation of the ISR: heme-regulated inhibitor kinase (HRI) in response to heme deficiency or oxidative stress, protein kinase R (PKR) in response to double-strand RNA (viruses), PERK (EIF2AK3) in response to the unfolded protein response and hypoxia, and GCN2 (EIF2AK4) in response to amino acid deprivation or UV light. Findings and observations that could conceivably affect all four of these kinases have been documented in the cornea; the presence of hemosiderin in Fleischer rings as an example of heme dysfunction, exposure to the environment as a source of pathogens and UV light, blinking and sleep as a source of hypoxia, and the unique way in which nutrients are delivered to the cornea as a source of nutrient deprivation. Based on our previous results, we believe that the unfolded protein response is a key driver of KC as we were able to exclude differences based on three of the four kinases within our in vitro model. Specifically, we observed persistence of signaling in vitro where extracellular sources of stimulation had been removed.

Although ISR stimulation can be achieved through multiple small molecules, we sought to use the cell-permeable analogue of salubrinal, SAL005, to stimulate the ISR through accumulation of p-eIF2α. This was based on our own experience with the other small molecule TUN, which is highly toxic (<0.1 μg/mL) over the duration of cultures studied here. We hypothesized that in KC, ISR activity can be caused by additive effects of activation from more than one of the ISR activating kinases; therefore SAL003 treatment would recapitulate the broadest spectrum of disease, although the nature of the ISR stimulation is still elusive and may well be different across the spectrum of patients.

The “cascade hypothesis” of keratoconus suggested that abnormal lipids and nitric oxide cause accumulation of cytotoxic components that trigger the apoptosis of keratocytes and the failure of the tissue. The interplay between redox state and the ISR has been described previously in other cell types, although the results seem to be dependent on context. The results presented here support this hypothesis that intracellular stress is a leading driver of keratoconus progression.

Interestingly, the observation that MMP9 transcriptional levels are unaffected by ISR activation may lead to further understanding of the cascade to failure seen in KC. Under normal homeostasis the turnover of the cornea is balanced between degradation, mostly by MMPs, and collagen production. However, in the context of an active ISR this axis is tilted toward degradation. As the ECM is a major reservoir of inactive MMPs, this change in homeostasis may be sufficient to cause release and activation of these catabolic enzymes, setting up the runaway failure that is characteristic of the disease (Fig. 5). Indeed, it is only at the final stages of the disease that new collagen, in the form of scarring, is identified.

Further investigations will focus on determining the status and nature of the unfolded protein response within patient populations. Of note is that none of the patients from which the KC fibroblasts were derived reported a family history of KC, further complicating the search for the triggers of the disease. However, these results showed consistency across the diverse patient population tested and correlate with several findings from the literature on the nature of the KC ECM phenotype. Therefore, if perturbation of the ISR pathway in KC fibroblasts proves to be nontoxic in vivo and the in vitro effects persist, targeting of the ISR in KC patients could provide an avenue of investigation for pharmacological intervention in the disease.

Acknowledgments

Supported by The Marfan Foundation’s Victor A. McKusick Fellowship Program (JWF), a Research to Prevent Blindness departmental grant (JWF), a generous donation from the Small family (JWF), National Institutes of Health Grant K08EY027474 (USS), and EY026104 (SC).

Disclosure: U.S. Soiberman, None; A.E.M. Shehata, None; M.X. Lu, None; T. Young, None; Y.J. Daoud, None; S. Chakravarti, None; A.S. Jun, None; J.W. Foster, None

References


